Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 33 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
GERPINNES PHARMA from Gerpinnes, company number BE0475932676, closed financial year 2025 with a result of € 12,354 after tax. For that financial year GERPINNES PHARMA recorded a gross margin of € 408,380 and equity of € 438,945. Compared with financial year 2024, the result moved from € -43,085 to € 12,354. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 438,945
▲ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 12,354
▲ still € 43,085 loss in 2024
Profit after tax over the fiscal year.
€ 302,120
▲ 1% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -423,055.
People and assets in 2025
€ 231,767
▲ 40% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 26,930
▼ 17% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 844,499
▼ 49% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 46,082
▲ 170% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 313,274 | € 327,388 | € 274,616 | € 408,380 | ▲ 49% |
| Profit after taxes | € -44,674 | € -39,774 | € -43,085 | € 12,354 | ▲ € 55,439 |
| Equity | € 509,450 | € 469,676 | € 426,591 | € 438,945 | ▲ 3% |
| Total debts | € 2,031,393 | € 1,886,211 | € 1,720,086 | € 1,642,015 | ▼ 5% |
| Cash | € 443,746 | € 292,872 | € 299,767 | € 302,120 | ▲ 1% |
| Land & buildings | € 1,319,588 | € 1,347,790 | € 1,260,360 | € 1,136,166 | ▼ 10% |
| Retained profit | € -352,550 | € -392,324 | € -435,409 | € -423,055 | ▲ € 12,354 |
| Balance sheet total | € 2,540,843 | € 2,355,887 | € 2,146,677 | € 2,080,960 | ▼ 3% |
Key figures of GERPINNES PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to GERPINNES PHARMA?
What happened at GERPINNES PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- FINPHARMA SA stepped down as director. NBB
- GESTIPHARMA SA stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 12,354. Source: NBB ↗
- FINPHARMA SA became a director. NBB
- GESTIPHARMA SA became a director. NBB
- New establishment in Gerpinnes. KBO
- New establishment in Gerpinnes. KBO
- Start of the company according to the CBE. KBO
In short
From € 44,674 loss in 2022 to € 12,354 profit in 2025.
Paid € 713 in corporate taxes since 2022.
Best year ever: 2025, with € 12,354 profit.
A new publication or filing at GERPINNES PHARMA? We notify you, reason included.
Follow GERPINNES PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
FINPHARMA SA
Director · represented by PHILIPPE BOULANGER
Also active at: Les Pharmacies Réunies, P.J. VLEUGELS et Cie, GESTIPHARMA, PHARMANET, FINANCIERE DU LOUVY
since 2021 · until 2027
Managing director · represented by PIERRE PASCAL HECQ
Also active at: Les Pharmacies Réunies, Immobilière Général Léman, P.J. VLEUGELS et Cie, EVRAS, Les Pharmacies du Louvy, PHARMACIE CLAERHOUT, FARMIMMO, IMMOBILIERE SAINT GEORGES +12 more
since 2021 · until 2027
Establishments
Establishment units
Physical locations of this company
Place de la Halle(GER) 3
6280 Gerpinnes
Rue des Flaches(GER) 48
6280 Gerpinnes
Active since 19 December 2001
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
DSTNY-ULYSSE, BE
Domain
Domain
universalpharma.be
Registered
2001-10-03
Website info
Features
Security
Details
- Company number
- 0475.932.676
- VAT number
- BE 0475.932.676
- Registered office
- Place de la Halle(GER) 3, 6280 Gerpinnes
- Names & denominations
- GERPINNES PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 24 October 2001
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- universalpharma.be
- Activities · NACE
Detailhandel in farmaceutische producten